葡萄膜黑色素瘤的免疫治疗进展

Progress in immunotherapy for uveal melanoma

葡萄膜黑色素瘤(UM)一旦发生远处转移,患者中位生存期少于12个月。目前临床缺乏转移性UM的标准治疗方式。近年,免疫治疗在肿瘤领域中异彩纷呈,免疫检查点、癌症疫苗、T细胞过继治疗被应用于UM治疗。但大多临床效果有限,生存获益不高,近期新型免疫治疗药物IMCgp100早期研究结果令人鼓舞。

Once uveal melanoma(UM)has distant metastasis,the median survival time of the patient is less than 12 months.There is currently a lack of standard treatment for metastatic UM.In recent years,immunotherapy is splendid in the field of oncology.Immune checkpoint therapy,cancer vaccine therapy and T cell adoptive therapy have been applied to UM therapy.However,most of the clinical effects are limited and the survival benefit is not high.The recent early research results of the new immunotherapeutic drug IMCgp100 are encouraging.